+

WO1991007437A3 - Anticorps cd-30 ameliores et fragments de ces derniers - Google Patents

Anticorps cd-30 ameliores et fragments de ces derniers Download PDF

Info

Publication number
WO1991007437A3
WO1991007437A3 PCT/US1990/006802 US9006802W WO9107437A3 WO 1991007437 A3 WO1991007437 A3 WO 1991007437A3 US 9006802 W US9006802 W US 9006802W WO 9107437 A3 WO9107437 A3 WO 9107437A3
Authority
WO
WIPO (PCT)
Prior art keywords
hodgkin
disease
chain
cells
compositions
Prior art date
Application number
PCT/US1990/006802
Other languages
English (en)
Other versions
WO1991007437A2 (fr
Inventor
Michael Pfreundschuh
Original Assignee
Parker David L
Michael Pfreundschuh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker David L, Michael Pfreundschuh filed Critical Parker David L
Publication of WO1991007437A2 publication Critical patent/WO1991007437A2/fr
Publication of WO1991007437A3 publication Critical patent/WO1991007437A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Sont décrits des procédés et des compositions relatifs au traitement de la maladie de Hodgkin ainsi que des procédés impliquant des cellules porteuses de la maladie de Hodgkin ou porteuses de la maladie de Reed-Sternberg, comprenant l'élimination spécifique des cellules atteintes par la maladie de Steinberg au moyen d'une technique aux immunotoxines. Les compositions de l'invention comprennent des conjugués de toxines composés d'un ligand de liaison des cellules infectées par la maladie de Hodgkin conjugué à une fraction de chaîne de toxine A comme la chaîne de ricine A ou la chaîne de ricine A déglycosylée, à l'aide d'un agent de réticulation ou d'une autre liaison conjuguée comprenant une liaison bisulfure. Dans des formes d'exécution préférées de l'invention, des doses thérapeutiques de conjugués sont administrées à un patient atteint par la maladie de Hodgkin afin d'éliminer de manière spécifique les cellules infectées par la maladie, sans être particulièrement toxiques pour les cellules non tumorales. Ces conjugués sont composés d'un anticorps CD-30 ou IRac ou d'un fragment de celui-ci conjugué à la chaîne A déglycosylée, à l'aide d'une liaison SMPT. Sont également décrits des hybrides et des anticorps monoclonaux spécifiques, ainsi qu'une méthodologie associée, que l'on peut employer, par exemple, pour préparer ces immunotoxines. D'autres utilisations sont également possibles comme des applications au niveau du diagnostic.
PCT/US1990/006802 1989-11-20 1990-11-20 Anticorps cd-30 ameliores et fragments de ces derniers WO1991007437A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44005189A 1989-11-20 1989-11-20
US440,051 1989-11-20

Publications (2)

Publication Number Publication Date
WO1991007437A2 WO1991007437A2 (fr) 1991-05-30
WO1991007437A3 true WO1991007437A3 (fr) 1991-06-27

Family

ID=23747219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/006802 WO1991007437A2 (fr) 1989-11-20 1990-11-20 Anticorps cd-30 ameliores et fragments de ces derniers

Country Status (2)

Country Link
AU (1) AU6909191A (fr)
WO (1) WO1991007437A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU666388B2 (en) * 1992-05-26 1996-02-08 Immunex Corporation Novel cytokine that binds CD30
AU4953693A (en) * 1992-08-25 1994-03-15 Medac Gesellschaft Fur Klinische Spezialpraparate Mbh Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
DE4337197C1 (de) * 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
ES2141467T5 (es) * 1995-01-18 2006-07-16 Roche Diagnostics Gmbh Anticuerpos anti-cd30 que evitan la escision proteolitica y liberacion del antigeno cd30 fijado a la membrana.
CA2222247A1 (fr) * 1995-06-07 1996-12-19 Innogenetics N.V. Immunotoxines specifiques aux cellules exprimant cd80 et cd86
DE19543039C1 (de) * 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
WO1999040187A1 (fr) * 1998-02-06 1999-08-12 Hinrich Abken Acides nucleiques pour la modulation de l'activation cellulaire
WO2002017970A2 (fr) * 2000-08-28 2002-03-07 Ludwig Institute For Cancer Research Anticorps de cd-30 etiquetes par radionucleides metalliques et leur utilisation
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
WO2003043583A2 (fr) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Traitement des troubles immunologiques au moyen des anticorps anti-cd30
CN1638800B (zh) 2002-01-09 2014-07-16 梅达雷克斯有限责任公司 抗cd30的人类单克隆抗体
US7790160B2 (en) 2004-10-01 2010-09-07 Medarex, Inc. Method of treating CD30 positive lymphomas
AU2006214033B2 (en) 2005-02-18 2011-08-11 Medarex, L.L.C. Monoclonal antibodies against CD30 lacking fucosyl residues

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Anticancer Research, volume 8, 1988, (Athens, GR), M. Pfreundschuh et al.: "Hodgkin and reed-sternberg cell associated monoclonal antibodies HRS-1 and HRS-2 react with activated cells of lymphoid and monocytoid origin", pages 217-224 see page 217, abstract; page 219, table 1 cited in the application *
Cancer Research, volume 48, 1988, (Philadelphia, US), M.A. Chetie et al.: "Evalution of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignan human B-cells as potential reagents for in vivo therapy1", pages 2610-2617, see page 2610, abstract cited in the application *
Cancer Research, volume 50, 1 January 1990, (Philadelphia, US), A. Engert et al.: "Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease1", pages 84-88 see page 84, abstract *
Cancer Research, volume 50, 15 May 1990, (Philadelphia, US), A. Engert et al.: "Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and fab fragments on solid human Hodgkin's disease tumors in mice1", pages 2929-2935 see page 2929, abstract *
Cancer Surveys, volume 4, no. 2, 1985 (Oxford, GB), V. Diehl et al.: "Phenotypic and genotypic analysis of Hodgkin's disease derived cell lines: histopatholigical and clinical implications", pages 399-419 see pages 399-400, summary; page 403, table 2; page 411-412, especially page 411, line 116 *
Leucocyte Typing, volume 3, 1987, A.J. Michel (ed.), Oxford, University Press, (Oxford, GB), R. Schwarting et al.: "BER-H2: a new monoclonal antidody of the Ki-1 family for the detection of Hodgkin's disease in formaldehyde-fixed tissue sections", pages 574-575 see the whole article cited in the application *

Also Published As

Publication number Publication date
AU6909191A (en) 1991-06-13
WO1991007437A2 (fr) 1991-05-30

Similar Documents

Publication Publication Date Title
WO1991007941A3 (fr) Methodes et composition pour le traitement de la maladie de hodgkin
Conde et al. The Aspergillus toxin restrictocin is a suitable cytotoxic agent for generation of immunoconjugates with monoclonal antibodies directed against human carcinoma cells
Ghetie et al. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy
AU622415B2 (en) Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
Engert et al. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease
US6096311A (en) Methods for use of monoclonal antibodies specific for the high affinity Fc receptor for immunoglobulin G
US4450154A (en) Antitumor hybrid and process for the preparation thereof
EP0055575B1 (fr) Hybride protéique cytotoxique et procédé pour sa préparation
Letvin et al. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. In vivo stability of disulfide-linked immunotoxin conjugates.
Sivam et al. Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates
EP0055115B1 (fr) Hybride protéique cytotoxique et son procédé de préparation
WO1991007437A3 (fr) Anticorps cd-30 ameliores et fragments de ces derniers
Ghetie et al. Chemical construction of immunotoxins
US5024834A (en) Thioether linked immunotoxin conjugates
Ghetie et al. Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin A chain using different cross-linkers
CA2006629A1 (fr) Agents de liaison avec empechement sterique; procedes
Wawrzynczak et al. Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer
EP0248040B1 (fr) Composes conjugues a des anticorps de ricine
Pietersz et al. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity
Bolognesi et al. Anti-CD30 immunotoxins with native and recombinant dianthin 30
Morgan Jr et al. Immunotoxins of Pseudomonas exotoxin A (PE): effect of linkage on conjugate yield, potency, selectivity and toxicity
Gasanov et al. In vitro evaluation of Pyrularia thionin—anti-CD5 immunotoxin
Siegall et al. Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F (ab') 2, and Fab'conjugated to Pseudomonas exotoxin
Vallera et al. Therapy for ongoing graft-versus-host disease induced across the major or minor histocompatibility barrier in mice with anti-CD3F (ab') 2-ricin toxin A chain immunotoxin
Barbieri et al. Blood clearance and organ distribution and tissue concentration of native, homopolymerized and IgG-conjugated ribosome-inactivating proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载